These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2072780)

  • 1. [Practical usefulness of serologic tumor markers in carcinoma of the lung].
    González Barón M; Espinosa Arranz J; de la Gándara Porres I; García de Paredes ML
    Med Clin (Barc); 1991 May; 96(18):707-10. PubMed ID: 2072780
    [No Abstract]   [Full Text] [Related]  

  • 2. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
    J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tumor markers in lung cancer].
    Niho S; Shinkai T
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of serum tumor markers in head and neck cancer.
    Martin M; Rayo JI; Talavera JR; Muñoz A; Cañizo A
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):235-8. PubMed ID: 2092125
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tumor markers in the diagnosis and follow-up assessment of bronchial carcinoma].
    Fischbach W
    Dtsch Med Wochenschr; 1989 May; 114(20):800-5. PubMed ID: 2656177
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer.
    Nieder C; Andratschke N; Jeremic B; Molls M
    Anticancer Res; 2003; 23(6D):5117-23. PubMed ID: 14981976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of tumor markers in patients on chronic hemodialysis].
    Kuno T; Kaizu K
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():391-4. PubMed ID: 15250332
    [No Abstract]   [Full Text] [Related]  

  • 9. [Lung cancer].
    Komagata H; Yoneda S
    Gan To Kagaku Ryoho; 2004 Oct; 31(10):1609-13. PubMed ID: 15508459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tumor marker in lung cancer].
    Shijubo N; Abe S
    Kokyu To Junkan; 1993 Jun; 41(6):551-5. PubMed ID: 7687790
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic markers for stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N
    Lung Cancer; 2008 Feb; 59(2):274-5. PubMed ID: 18055061
    [No Abstract]   [Full Text] [Related]  

  • 12. [The possible approaches to prognosis in colorectal cancer].
    Teploukhova IM; Vvedenskaia NA; Papish EA
    Vopr Onkol; 1991; 37(6):651-6. PubMed ID: 1843140
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.
    Buccheri G; Ferrigno D
    J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative studies of CAM 123-6 and carcinoembryonic antigen for the serological detection of pulmonary adenocarcinoma.
    Kohno N; Hirasawa Y; Kondo K; Fujioka S; Fujino S; Abe M; Yokoyama A; Hiwada K; Watanabe K; Nishimura J
    Cancer Detect Prev; 1997; 21(2):124-8. PubMed ID: 9101072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tumor markers in uterine cancers].
    Fukasawa I; Kousaka N; Kun Z; Inaba N
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):333-40. PubMed ID: 11865645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
    Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
    Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The value of marker antigens TPS, SCC and CEA in diagnosis, evaluation of histologic type and clinical disease progression in patients with cervical carcinoma].
    Zakrzewska I
    Pol Merkur Lekarski; 2001 Jan; 10(55):21-3. PubMed ID: 11320545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple tumour markers for diagnosis, management and follow-up of potentially resectable lung cancer.
    Ratto GB; Mereu C; Rovida S
    Panminerva Med; 1993 Dec; 35(4):186-92. PubMed ID: 8202329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEA, TPA, CA 19-9, SCC and CYFRA at diagnosis and in the follow-up of anal canal tumors.
    Indinnimeo M; Reale MG; Cicchini C; Stazi A; Fiori E; Izzo P
    Int Surg; 1997; 82(3):275-9. PubMed ID: 9372374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Cyfra 21-1 as a marker for lung cancer.
    Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
    Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.